Shares of Concord Medical Services Hldg Ltd (NYSE:CCM) have been given an average broker rating score of 3.70 (Sell) from the one analysts that provide coverage for the company, Zacks Investment Research reports. One analyst has rated the stock with a sell rating.
Brokerages have set a 1 year consensus price target of $3.00 for the company and are predicting that the company will post $0.01 earnings per share for the current quarter, according to Zacks. Zacks has also assigned Concord Medical Services an industry rank of 65 out of 256 based on the ratings given to its competitors.
Separately, Zacks Investment Research upgraded Concord Medical Services from a “sell” rating to a “hold” rating in a research report on Wednesday, September 19th.
About Concord Medical Services
Concord Medical Services Holdings Limited, through its subsidiaries, operates a network of radiotherapy and diagnostic imaging centers in the People's Republic of China. The company's services comprise linear accelerators external beam radiotherapy, gamma knife radiosurgery, head gamma knife systems, body gamma knife systems, CyberKnife robotic radiosurgery system, proton beam therapy systems, and diagnostic imaging services.
Featured Story: What is a good rate of return for a mutual fund?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Concord Medical Services Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Concord Medical Services and related companies with MarketBeat.com's FREE daily email newsletter.